Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 20/20 | 0.45 |
| ▸ | CA2 | P00918 | 20/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | CA5A | P35218 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936191 | 0.94 | CA1 (0.48) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3936840 | 0.93 | CA1 (0.40) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3944827 | 0.92 | CA1 (0.46) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3937628 | 0.91 | CA1 (0.49) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL14304742 | 0.91 | CA1 (0.47) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL4140860 | 0.91 | CA1 (0.47) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3942950 | 0.89 | CA1 (0.43) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3939423 | 0.89 | CA1 (0.43) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3938422 | 0.89 | CA1 (0.45) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3937079 | 0.89 | CA2 (0.43) | CA1CA2CA12CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046731-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008009613-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, HPRT1, NQO2 | CA1 4554/4885CA2 4383/4885CA12 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.